Emmes and MedGenome have announced a strategic partnership aimed at accelerating the delivery of breakthrough rare disease treatments through the use of genomics data.

Emmes and MedGenome will work together to compile epidemiologic, phenotypic and genomic patient data into customized disease registries that can be used by sponsors to improve designs, ramp up patient recruitment and deliver standardized control arms for rare disease clinical trials.

MedGenome is the leading genetic testing laboratory in India and South Asia, said Vedam Ramprasad, CEO of MedGenome, who noted that the South Asia region has the highest numbers of rare and inherited disease patients in the world.

Emmes has made moves this year to expand its rare disease capabilities, launching a new rare disease center in November and buying up the UK-based Orphan Reach, a CRO specializing in rare disease research, back in May.

The pair intend to focus on hemophilia, Duchenne muscular dystrophy and muscular atrophies and retinitis pigmentosa.